Vaccitech to Present at Upcoming September Investor conferences
Vaccitech plc (NASDAQ: VACC), a biopharmaceutical firm focused on immunotherapeutics and vaccines, has announced upcoming presentations by CEO Bill Enright at key investment conferences in September. He will speak at the Morgan Stanley Healthcare Conference on September 9, in a fireside chat at 11:45 a.m. EDT, available via webcast. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, with an on-demand presentation and a panel discussion on pandemic preparedness.
- None.
- None.
OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September.
| Event: | Morgan Stanley Healthcare Conference 2021 |
| Date: | Thursday, September 9 |
| Presentation: | Fireside chat |
| Time: Webcast: | 11:45 a.m. EDT Events section of the Vaccitech website |
| Event: | H.C. Wainwright 23rd Annual Global Investment Conference |
| Date: | Monday, September 13 - Wednesday, September 15 |
| Presentation: Panel: | On demand, virtual presentation On demand, Best Practices – Planning for the Next Pandemic |
| Time: Webcast: | 7 a.m. EDT Requires conference portal log-in |
About Vaccitech plc
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com
Robert Flamm, Ph.D. / Harrison Wong, Burns McClellan, Inc. (US)
212-213-0006 ext. 364 / 316
Email: rflamm@burnsmc.com / hwong@burnsmc.com
Henry Hodge, Vaccitech (UK)
Email: henry.hodge@vaccitech.co.uk
FAQ
What conferences is Vaccitech presenting at in September 2021?
When is Bill Enright speaking at the Morgan Stanley Healthcare Conference?
What is the format of the presentation at H.C. Wainwright Conference?
How can I access the webcast for Vaccitech's presentations?
What is the stock symbol for Vaccitech?
